ReviewMini reviews in medicinal chemistry2026
The Nasal Route Redefined: The Impact of Chitosan Nanoparticles on Drug Delivery.
Review in Mini reviews in medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe nasal route presents a viable alternative for medication administration, circumventing first-pass metabolism and improving bioavailability, especially for neurological conditions. Nonetheless, obstacles such as mucociliary clearance and enzymatic degradation constrain its effectiveness. Chitosan nanoparticles (CS-NPs) have emerged as a viable option due to their mucoadhesive properties, biocompatibility, and capacity to modulate tight junctions, thereby enabling direct nose-to-brain administration.
methodsThis review explores various methods for the production of chitosan nanoparticles (CSNPs), their characterization techniques, drug delivery applications via the nasal route, and an examination of related patents. Search engines such as PubMed, Google Scholar, and ScienceDirect were utilized for the literature search. Studies published between 2015 and 2025 were included.
resultsThe use of CS-NPs in the delivery of various treatments, including anticancer, antiparkinsonian, antianxiety, and antischizophrenic medications, shows great promise. Research has demonstrated that certain formulations, such as chitosan-PEG nanovesicles and transferrin-conjugated nanoparticles, exhibit improved bioavailability, sustained release, and enhanced brain targeting. Patents have further supported the development of mucoadhesive and combinatorial therapies. DISCUSSION: While there are notable benefits, obstacles such as rapid mucociliary clearance, limited drug-loading capacity, and variability in nasal responses persist. Proposed solutions to address these challenges include innovations like mucoadhesive coatings, hybrid polymers, and stimuli-responsive systems. Utilizing computational modeling and conducting clinical trials are crucial for improving formulations.
conclusionCS-NPs represent a transformative approach to nasal medication delivery. To fully realize their potential, future research should focus on advanced formulations and personalized delivery systems, thereby facilitating clinical translation and improving therapeutic outcomes.
Indexed as
Identifiers
41830574What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.